Esbriet pirfenidone regulatory update

InterMune disclosed in its 2Q13 earnings that Ireland's Health Service Executive (HSE) granted reimbursement for Esbriet pirfenidone to treat mild to moderate idiopathic pulmonary fibrosis (IPF), effective Aug. 1. InterMune said Esbriet is priced at €36,036.51 ($47,881.71) per patient per year in Ireland. ...